ROCHE HOLDING AG

Roche’s 1H 2026 results show a 6 % currency‑neutral revenue rise amid a strong Swiss franc, reaffirming UBS’s Buy rating and highlighting resilient core growth and a robust oncology pipeline.

Roche’s Tecentriq gets FDA approval for adjuvant muscle‑invasive bladder cancer, boosting its oncology pipeline and share value through precision ctDNA‑guided therapy.

Roche Holding AG faces political, legal, and competitive pressures that threaten its pricing power and employee compliance, prompting a dual strategy of regulatory engagement and operational excellence to safeguard its global pharmaceutical dominanc…

Roche Holding AG faces a turbulent day: new respiratory diagnostics promise growth, but recent therapeutic failures and hefty research spend cast doubt on future earnings.

Roche Holding AG shifts focus: stops SMA trials for its anti‑myostatin antibody, yet keeps exploring muscle‑growth in obesity, boosting its weight‑loss strategy.

Roche’s new Head of Pharma Research, Dr. Mark Dawson, powers a breakthrough Phase‑III win for Gazyva in kidney disease, positioning Roche for growth in rare‑disease therapy.

Roche Holding AG’s growth, oncology dominance, and new lupus drug are weighed against legal risks and pricing pressures—investors must track how it turns opportunity into lasting profit.

Roche’s oral SERD giredestrant shows a landmark IDFS benefit in early ER‑positive breast cancer, potentially redefining standard care and boosting patient outcomes.

Roche Holding AG has made significant strategic expansions in both its metabolic and diagnostic segments through the acquisition of 89bio and the certification of its Ionify 25-Hydroxy Vitamin D Test, solidifying its position as a leader in the heal…